Imatinib
Treatment for Chronic Myeloid Leukemia
Typical Dosage: 400 mg daily
Effectiveness
90%
Safety Score
65%
Clinical Trials
306
Participants
20K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
400 mg daily
Time to Effect
3-6 months for major response
Treatment Duration
Lifetime (or 5+ years for TFR attempts)
Evidence Quality
HIGHConfidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$8,000
Monitoring:$2,000
Side Effect Mgmt:$750
Total Annual:$10,750
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTQALYs Gained
10
Outcome-Based Costs
Cost per Responder
$14,333
Cost per Remission
$23,889
Imatinib Outcomes
for Chronic Myeloid Leukemia
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+75%
Remission Rate
+45%
Common Side Effects
Fluid retention (edema)
+60%
Muscle cramps
+35%
Nausea/vomiting
+40%
Diarrhea
+35%
Fatigue
+35%
Rash
+25%
Myelosuppression
+15%
Active Clinical Trials
2 active trials recruiting for Imatinib in Chronic Myeloid Leukemia
Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia
NCT05282108RECRUITING
240 participants
OBSERVATIONAL
Cairo, Egypt +3 more
Started: Jul 20, 2022
Long-term Risk of Second Primary Malignancies for Chronic Myeloid Leukaemia in the French Imatinib-based SPIRIT Trial
NCT06646978ENROLLING BY INVITATION
787 participants
OBSERVATIONAL
Poitiers, France
Started: May 1, 2024
Completed Clinical Trials
13 completed trials for Imatinib in Chronic Myeloid Leukemia
Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia
NCT00390897COMPLETEDPHASE4
360 participants
INTERVENTIONAL
Ávila, Spain +50 more
Started: Jul 1, 2003
Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib
NCT01475110COMPLETED
19 participants
OBSERVATIONAL
Rionero in Vulture, Italy +32 more
Started: Sep 13, 2012
An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis
NCT00171158COMPLETEDPHASE2
260 participants
INTERVENTIONAL
Chicago, United States +9 more
Started: Jul 26, 1999
Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib
NCT01343173COMPLETEDNA
220 participants
INTERVENTIONAL
Angers, France +31 more
Started: Apr 6, 2011
De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia
NCT01804985COMPLETEDPHASE2
174 participants
INTERVENTIONAL
Liverpool, United Kingdom
Started: Dec 1, 2013
Therapy of Early Chronic Phase CML With Gleevec
NCT00048672COMPLETEDPHASE2
50 participants
INTERVENTIONAL
Houston, United States
Started: Mar 1, 2001
Late Chronic Phase Chronic Myelogenous Leukemia
NCT01092741COMPLETEDPHASE2
47 participants
INTERVENTIONAL
Houston, United States
Started: Jul 1, 2001
Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia
NCT00079313COMPLETEDPHASE2
7 participants
INTERVENTIONAL
Bethesda, United States
Started: Jan 14, 2004
Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)
NCT00171899COMPLETEDPHASE4
80 participants
INTERVENTIONAL
Toronto, Canada
Started: Apr 1, 2005
Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
NCT00081926COMPLETEDPHASE4
112 participants
INTERVENTIONAL
East Hanover, United States
Started: Oct 1, 2003
Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia
NCT02001818COMPLETEDPHASE2
60 participants
INTERVENTIONAL
Adelaide, Australia
Started: Apr 11, 2014
Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database
NCT05286528COMPLETED
1.48K participants
OBSERVATIONAL
Budapest, Hungary
Started: Nov 18, 2020
Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib
NCT00802841COMPLETEDPHASE3
191 participants
INTERVENTIONAL
Caba, Argentina +55 more
Started: May 1, 2009
Showing 20 of 306 total trials